OBJECTIVES: Patients with chronic kidney disease (CKD) often present with reduced plasma HDL cholesterol (HDL-C) levels. Whether this reduction in an epiphenomenon or is involved in disease progression is unclear. The aim of this study was to investigate the relation between HDL-C levels/function and CKD progression in patients with different degrees of disease. DESIGN: A total of 176 patients with CKD [glomerular filtration rate (GFR) 50.3 ± 29.1 mL min⁻¹] were recruited and followed for up to 84 months. Lipid profile, metabolic status and kidney function were evaluated at predetermined times. Age-matched control subjects were selected from the PLIC study (n = 453). Scavenger receptor class B member 1 (SR-BI) and ATP-binding cassette transporter A1 (ABCA-1)-dependent efflux of cholesterol were measured in CKD patients and in age-matched control subjects. RESULTS: Low HDL-C levels, diabetes and hypertension were associated with reduced GFR. At follow-up, low HDL-C levels were associated with earlier entry in dialysis or doubling of the plasma creatinine level (P = 0.017); HDL-C levels were the only lipid parameter that affected the progression of CKD (hazard ratio 0.951, 95% confidence interval 0.917-0.986, P = 0.007), independently of the presence of diabetes. Only SR-BI-mediated serum cholesterol efflux was significantly reduced in the group of CKD patients with low HDL-C levels compared to the control group. CONCLUSIONS: CKD patients with low levels of plasma HDL-C have a poor prognosis. HDL functionality is also impaired in renal dysfunction. These data support the relevance of HDL in influencing CKD progression.
OBJECTIVES:Patients with chronic kidney disease (CKD) often present with reduced plasma HDL cholesterol (HDL-C) levels. Whether this reduction in an epiphenomenon or is involved in disease progression is unclear. The aim of this study was to investigate the relation between HDL-C levels/function and CKD progression in patients with different degrees of disease. DESIGN: A total of 176 patients with CKD [glomerular filtration rate (GFR) 50.3 ± 29.1 mL min⁻¹] were recruited and followed for up to 84 months. Lipid profile, metabolic status and kidney function were evaluated at predetermined times. Age-matched control subjects were selected from the PLIC study (n = 453). Scavenger receptor class B member 1 (SR-BI) and ATP-binding cassette transporter A1 (ABCA-1)-dependent efflux of cholesterol were measured in CKD patients and in age-matched control subjects. RESULTS: Low HDL-C levels, diabetes and hypertension were associated with reduced GFR. At follow-up, low HDL-C levels were associated with earlier entry in dialysis or doubling of the plasma creatinine level (P = 0.017); HDL-C levels were the only lipid parameter that affected the progression of CKD (hazard ratio 0.951, 95% confidence interval 0.917-0.986, P = 0.007), independently of the presence of diabetes. Only SR-BI-mediated serum cholesterol efflux was significantly reduced in the group of CKD patients with low HDL-C levels compared to the control group. CONCLUSIONS: CKD patients with low levels of plasma HDL-C have a poor prognosis. HDL functionality is also impaired in renal dysfunction. These data support the relevance of HDL in influencing CKD progression.
Authors: Kathryn C B Tan; Ching-Lung Cheung; Alan C H Lee; Joanne K Y Lam; Ying Wong; Sammy W M Shiu Journal: Clin J Am Soc Nephrol Date: 2020-02-19 Impact factor: 8.237
Authors: Chantal Kopecky; Michael Haidinger; Ruth Birner-Grünberger; Barbara Darnhofer; Christopher C Kaltenecker; Gunther Marsche; Michael Holzer; Thomas Weichhart; Marlies Antlanger; Johannes J Kovarik; Johannes Werzowa; Manfred Hecking; Marcus D Säemann Journal: J Am Soc Nephrol Date: 2014-07-28 Impact factor: 10.121
Authors: Chantal Kopecky; Bernd Genser; Christiane Drechsler; Vera Krane; Christopher C Kaltenecker; Markus Hengstschläger; Winfried März; Christoph Wanner; Marcus D Säemann; Thomas Weichhart Journal: Clin J Am Soc Nephrol Date: 2014-11-25 Impact factor: 8.237
Authors: Andrea Romagnani; Elsa Rottoli; Emilia Maria Cristina Mazza; Tanja Rezzonico-Jost; Benedetta De Ponte Conti; Michele Proietti; Michela Perotti; Elisa Civanelli; Lisa Perruzza; Alberico L Catapano; Andrea Baragetti; Elena Tenedini; Enrico Tagliafico; Simonetta Falzoni; Francesco Di Virgilio; Giuseppe Danilo Norata; Silvio Bicciato; Fabio Grassi Journal: Cancer Res Date: 2020-07-22 Impact factor: 12.701